Esperion Therapeutics (NASDAQ:ESPR) Releases Quarterly Earnings Results

Key Points

• Esperion Therapeutics reported a quarterly loss of ($0.02) earnings per share, surpassing expectations of ($0.17) by $0.15, with generated revenues of $82.39 million compared to estimates of $62.55 million.
• Following the earnings announcement, Esperion's stock rose by 8.7% to $1.62, with a market capitalization of $321.08 million.
• Several analysts have mixed ratings on the stock, with price targets ranging from $3.00 to $16.00, leading to a consensus rating of "Moderate Buy" with an average price target of $7.00.

Esperion Therapeutics (NASDAQ:ESPR - Get Free Report) posted its earnings results on Tuesday. The biopharmaceutical company reported ($0.02) EPS for the quarter, topping the consensus estimate of ($0.17) by $0.15, Zacks reports. Esperion Therapeutics had a negative return on equity of 0.91% and a negative net margin of 35.84%. The firm had revenue of $82.39 million for the quarter, compared to analyst estimates of $62.55 million.

Esperion Therapeutics Stock Performance

Shares of ESPR stock traded up $0.06 during trading hours on Friday, reaching $1.87. The company had a trading volume of 5,148,622 shares, compared to its average volume of 5,630,319. Esperion Therapeutics has a 12-month low of $0.69 and a 12-month high of $3.94. The company has a market capitalization of $370.63 million, a price-to-earnings ratio of -3.82 and a beta of 0.82. The stock has a fifty day moving average of $1.24 and a 200-day moving average of $1.32.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on ESPR shares. The Goldman Sachs Group lowered their price target on shares of Esperion Therapeutics from $4.00 to $3.00 and set a "neutral" rating on the stock in a report on Thursday, April 17th. Wall Street Zen raised Esperion Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday. HC Wainwright reaffirmed a "buy" rating and set a $16.00 target price on shares of Esperion Therapeutics in a research note on Tuesday, June 17th. Finally, Needham & Company LLC dropped their price target on shares of Esperion Therapeutics from $5.00 to $4.00 and set a "buy" rating on the stock in a research note on Wednesday, May 7th. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $7.00.

Hedge Funds Weigh In On Esperion Therapeutics

A hedge fund recently bought a new stake in Esperion Therapeutics stock. Jones Financial Companies Lllp bought a new stake in shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 192,743 shares of the biopharmaceutical company's stock, valued at approximately $278,000. Jones Financial Companies Lllp owned 0.10% of Esperion Therapeutics at the end of the most recent reporting period. 47.39% of the stock is owned by hedge funds and other institutional investors.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.